{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:54:30Z","timestamp":1782996870982,"version":"3.54.5"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["30144"],"award-info":[{"award-number":["30144"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","award":["194133"],"award-info":[{"award-number":["194133"]}],"id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["22 2448 Pj"],"award-info":[{"award-number":["22 2448 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2020-01750"],"award-info":[{"award-number":["2020-01750"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.semcancer.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:47:21Z","timestamp":1776440841000},"page":"16-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Therapy-driven clonal dynamics in chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"122","author":[{"given":"Larry","family":"Mansouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chatzikonstantinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Scarf\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0211-8788","authenticated-orcid":false,"given":"Richard","family":"Rosenquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2026.04.001_bib1","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2026.04.001_bib2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.04.001_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.04.001_bib4","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2026.04.001_bib5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1084\/jem.20142009","article-title":"Functional loss of IkappaBepsilon leads to NF-kappaB deregulation in aggressive chronic lymphocytic leukemia","volume":"212","author":"Mansouri","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2026.04.001_bib6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Puente","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.semcancer.2026.04.001_bib7","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41588-022-01140-w","article-title":"Molecular map of chronic lymphocytic leukemia and its impact on outcome","volume":"54","author":"Knisbacher","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2026.04.001_bib8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2026.04.001_bib9","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2026.04.001_bib10","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2011-12-395673","article-title":"Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib11","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2015-10-674572","article-title":"Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations","volume":"127","author":"Ljungstrom","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib12","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.04.001_bib13","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","article-title":"BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib","volume":"7","author":"Bonfiglio","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2026.04.001_bib14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.semcancer.2026.04.001_bib15","doi-asserted-by":"crossref","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.semcancer.2026.04.001_bib16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood-2015-02-585042","article-title":"Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia","volume":"126","author":"Gui\u00e8ze","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib17","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJM199009133231105","article-title":"Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities","volume":"323","author":"Juliusson","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.04.001_bib18","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.04.001_bib19","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3324\/haematol.10720","article-title":"Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival","volume":"92","author":"Stilgenbauer","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.04.001_bib20","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1038\/sj.leu.2404935","article-title":"Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping","volume":"21","author":"Haferlach","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.04.001_bib21","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","article-title":"Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact","volume":"133","author":"Baliakas","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2019.239947","article-title":"Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study","volume":"106","author":"Leeksma","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.04.001_bib23","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2010.039768","article-title":"Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia","volume":"96","author":"Gunnarsson","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.04.001_bib24","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/leu.2017.291","article-title":"Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia","volume":"32","author":"Nadeu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.04.001_bib25","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.04.001_bib26","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3324\/haematol.2018.187583","article-title":"TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics","volume":"103","author":"Campo","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.04.001_bib27","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-08-1630","article-title":"The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2026.04.001_bib28","doi-asserted-by":"crossref","first-page":"E2911","DOI":"10.1073\/pnas.1702564114","article-title":"Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia","volume":"114","author":"Fabbri","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.semcancer.2026.04.001_bib29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/leu.2015.182","article-title":"NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation","volume":"30","author":"Pozzo","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.04.001_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2012","journal-title":"Nat. Genet"},{"key":"10.1016\/j.semcancer.2026.04.001_bib31","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/leu.2012.307","article-title":"NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia","volume":"27","author":"Mansouri","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.04.001_bib32","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1182\/blood-2011-08-373159","article-title":"Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib33","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3324\/haematol.2019.219550","article-title":"Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia","volume":"105","author":"Diop","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.04.001_bib34","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.2007.11.2649","article-title":"Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion","volume":"25","author":"Austen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.04.001_bib35","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semcancer.2026.04.001_bib36","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41375-025-02615-5","article-title":"ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker","volume":"39","author":"Thorvaldsdottir","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.04.001_bib37","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/2159-8290.CD-14-0104","article-title":"Acquired initiating mutations in early hematopoietic cells of CLL patients","volume":"4","author":"Damm","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2026.04.001_bib38","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/leu.2016.359","article-title":"EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia","volume":"31","author":"Young","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.04.001_bib39","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2017-09-804401","article-title":"Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia","volume":"132","author":"Bretones","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib40","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1158\/1078-0432.CCR-18-4158","article-title":"The number of signaling pathways altered by driver mutations in chronic lymphocytic leukemia impacts disease outcome","volume":"26","author":"Brieghel","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2026.04.001_bib41","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","article-title":"Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia","volume":"123","author":"Rossi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib42","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ng.3488","article-title":"DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia","volume":"48","author":"Oakes","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2026.04.001_bib43","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ng.2443","article-title":"Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia","volume":"44","author":"Kulis","year":"2012","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.semcancer.2026.04.001_bib44","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s43018-020-00131-2","article-title":"The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome","volume":"1","author":"Duran-Ferrer","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.semcancer.2026.04.001_bib45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2014-10-604959","article-title":"Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia","volume":"126","author":"Rodriguez","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib46","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1038\/leu.2016.134","article-title":"Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia","volume":"30","author":"Parker","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.04.001_bib47","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/hematology.2019000367","article-title":"Clonal dynamics in chronic lymphocytic leukemia","volume":"2019","author":"Gutierrez","year":"2019","journal-title":"Hematology"},{"key":"10.1016\/j.semcancer.2026.04.001_bib48","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood-2017-07-731588","article-title":"FCR achieves long-term durable remissions in patients with IGHV-mutated CLL","volume":"130","author":"Chai-Adisaksopha","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib49","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2009-05-224071","article-title":"Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial","volume":"114","author":"Zenz","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semcancer.2026.04.001_bib50","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/leu.2016.317","article-title":"Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial","volume":"31","author":"Edelmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.04.001_bib51","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib52","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2005.05550.x","article-title":"Diagnostic criteria for monoclonal B-cell lymphocytosis","volume":"130","author":"Marti","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2026.04.001_bib53","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2015-02-585059","article-title":"Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification","volume":"126","author":"Strati","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib54","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2017.177212","article-title":"Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations","volume":"103","author":"Agathangelidis","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.semcancer.2026.04.001_bib55","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/leu.2016.172","article-title":"Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome","volume":"31","author":"Barrio","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.04.001_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067751","article-title":"Combined patterns of IGHV repertoire and cytogenetic\/molecular alterations in monoclonal B lymphocytosis versus chronic lymphocytic leukemia","volume":"8","author":"Henriques","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2026.04.001_bib57","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.seminoncol.2016.02.013","article-title":"What does it mean I have a monoclonal B-cell lymphocytosis?: Recent insights and new challenges","volume":"43","author":"Scarf\u00f2","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.semcancer.2026.04.001_bib58","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/leu.2014.226","article-title":"Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression","volume":"28","author":"Ojha","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.04.001_bib59","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1158\/0008-5472.CAN-14-0630","article-title":"Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution","volume":"74","author":"Vardi","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2026.04.001_bib60","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3324\/haematol.2013.098384","article-title":"The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy","volume":"99","author":"Packham","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.04.001_bib61","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2026.04.001_bib62","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41375-022-01802-y","article-title":"Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY","volume":"37","author":"Mansouri","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.semcancer.2026.04.001_bib63","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/bjc.2016.78","article-title":"The clinical implications of gene mutations in chronic lymphocytic leukaemia","volume":"114","author":"Rossi","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2026.04.001_bib64","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/leu.2008.260","article-title":"A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease","volume":"23","author":"Best","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.04.001_bib65","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood.2023023659","article-title":"Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib","volume":"144","author":"Woyach","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib66","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/bloodadvances.2024014206","article-title":"Acquired mutations in patients with relapsed\/refractory CLL who progressed in the ALPINE study","volume":"9","author":"Brown","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2026.04.001_bib67","doi-asserted-by":"crossref","first-page":"8747","DOI":"10.3390\/ijms26178747","article-title":"Richter transformation in chronic lymphocytic leukemia: current treatment challenges and evolving therapies","volume":"26","author":"Lin","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2026.04.001_bib68","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2013-11-516229","article-title":"How we treat Richter syndrome","volume":"123","author":"Parikh","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib69","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","article-title":"Biology and treatment of Richter syndrome","volume":"131","author":"Rossi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib70","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"8081","key":"10.1016\/j.semcancer.2026.04.001_bib71","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41586-025-09374-4","article-title":"Fluctuating DNA methylation tracks cancer evolution at clinical scale","volume":"645","author":"Gabbutt","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2026.04.001_bib72","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.3390\/ijms26125563","article-title":"Molecular features accompanying Richter\u2019s transformation in patients with chronic lymphocytic leukemia","volume":"26","author":"Wang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.semcancer.2026.04.001_bib73","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","article-title":"Detection of early seeding of Richter transformation in chronic lymphocytic leukemia","volume":"28","author":"Nadeu","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2026.04.001_bib74","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.2020005734","article-title":"Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1","volume":"137","author":"Kohlhaas","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib75","first-page":"11","article-title":"Richter syndrome: novel insights into the biology of transformation","volume":"142","author":"Parry","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib76","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1143811","article-title":"Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia","volume":"13","author":"Oder","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.semcancer.2026.04.001_bib78","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1182\/blood.2021014669","article-title":"The end of the beginning: application of single-cell sequencing to chronic lymphocytic leukemia","volume":"141","author":"Nagler","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcancer.2026.04.001_bib79","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1038\/s41467-022-33385-8","article-title":"Proteogenomics refines the molecular classification of chronic lymphocytic leukemia","volume":"13","author":"Herbst","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2026.04.001_bib80","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.04.001_bib81","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2026.04.001_bib82","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib83","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.semcancer.2026.04.001_bib84","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","article-title":"Orelabrutinib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.semcancer.2026.04.001_bib85","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.04.001_bib86","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib87","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2026.04.001_bib88","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO-24-02265","article-title":"Zanubrutinib versus bendamustine and rituximab in patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA","volume":"43","author":"Shadman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.04.001_bib89","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.2024024476","article-title":"Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN","volume":"146","author":"Sharman","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib90","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1039\/D0SC06122K","article-title":"Mechanism of covalent binding of ibrutinib to Bruton\u2019s tyrosine kinase revealed by QM\/MM calculations","volume":"12","author":"Voice","year":"2021","journal-title":"Chem. Sci."},{"issue":"1","key":"10.1016\/j.semcancer.2026.04.001_bib91","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/leu.2016.153","article-title":"Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant","volume":"31","author":"Hamasy","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.04.001_bib92","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2026.04.001_bib93","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood.2023023659","article-title":"Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib","volume":"144","author":"Woyach","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib94","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1182\/blood-2022-170985","article-title":"Novel BTK Mutations Conferring Resistance to the Second-Generation, Irreversible BTK Inhibitor Orelabrutinib (ICP-022)","volume":"140","author":"Zhu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib95","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance","volume":"6","author":"Blombery","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2026.04.001_bib96","doi-asserted-by":"crossref","first-page":"22136","DOI":"10.1074\/jbc.M116.746842","article-title":"The phospholipase C\u03b32 mutants R665W and L845F identified in ibrutinib-resistant chronic lymphocytic leukemia patients are hypersensitive to the Rho GTPase Rac2 Protein","volume":"291","author":"Walliser","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2026.04.001_bib97","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1158\/1078-0432.CCR-22-3887","article-title":"B-cell receptor pathway mutations are infrequent in patients with chronic lymphocytic leukemia on continuous ibrutinib therapy","volume":"29","author":"Woyach","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2026.04.001_bib98","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.2019000854","article-title":"Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study","volume":"134","author":"Quinquenel","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semcancer.2026.04.001_bib99","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41375-025-02662-y","article-title":"Resistance to targeted therapies in chronic lymphocytic leukemia: current status and perspectives for clinical and diagnostic practice","volume":"39","author":"Blombery","year":"2025","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.semcancer.2026.04.001_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.74","article-title":"Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients","volume":"5","author":"Boissard","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.semcancer.2026.04.001_bib101","doi-asserted-by":"crossref","first-page":"65968","DOI":"10.18632\/oncotarget.11782","article-title":"Ibrutinib modifies the function of monocyte\/macrophage population in chronic lymphocytic leukemia","volume":"7","author":"Fiorcari","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2026.04.001_bib102","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2016004176","article-title":"Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL","volume":"1","author":"Jayappa","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2026.04.001_bib103","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41375-024-02301-y","article-title":"Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia","volume":"38","author":"Pozzo","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.04.001_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.592205","article-title":"Proliferative signals in chronic lymphocytic leukemia; what are we missing?","volume":"10","author":"Haselager","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.semcancer.2026.04.001_bib105","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/leu.2017.100","article-title":"Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1","volume":"31","author":"Cosson","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.04.001_bib106","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2026.04.001_bib107","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/s41375-018-0335-2","article-title":"Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment","volume":"33","author":"Gounari","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.04.001_bib108","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.04.001_bib109","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO-25-00166","article-title":"Phase III trial of pirtobrutinib versus idelalisib\/rituximab or bendamustine\/rituximab in covalent bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma (BRUIN CLL-321)","volume":"43","author":"Sharman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.04.001_bib110","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.04.001_bib111","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000967496.62332.46","article-title":"S146: genomic evolution and resistance to pirtobrutinib in covalent BTK-inhibitor (CBTKI) pre-treated chronic lymphocytic leukemia (CLL) patients: results from the phase I\/II bruin study","volume":"7","author":"Brown","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.semcancer.2026.04.001_bib112","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2022009366","article-title":"BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib","volume":"7","author":"Jackson","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2026.04.001_bib113","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-797","article-title":"Genomic assessment of acquired mutations in participants with CLL\/SLL treated with nemtabrutinib in the Phase 2 bellwave-003 study","volume":"146","author":"Kipps","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib114","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3324\/haematol.2021.279158","article-title":"Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase","volume":"107","author":"Aslan","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.04.001_bib115","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2021.280061","article-title":"Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton\u2019s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies","volume":"107","author":"Allan","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.04.001_bib116","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.18632\/oncotarget.24310","article-title":"First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL","volume":"9","author":"Byrd","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2026.04.001_bib117","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","article-title":"BTK inhibitors in CLL: second-generation drugs and beyond","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2026.04.001_bib118","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-178259","article-title":"Targeting covalent and non-covalent Btki-resistant CLL using the dual irreversible\/reversible 4th generation BTK inhibitor LP-168","volume":"142","author":"Gordon","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib119","article-title":"Phase 1\/2 studies of DZD8586 in CLL\/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders \u2013 extended follow-up report","volume":"146","author":"Zhou","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.semcancer.2026.04.001_bib120","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41375-024-02317-4","article-title":"Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia","volume":"38","author":"Wong","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.semcancer.2026.04.001_bib121","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.semcancer.2026.04.001_bib122","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.04.001_bib123","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.04.001_bib124","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2026.04.001_bib125","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.04.001_bib126","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2026.04.001_bib127","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.04.001_bib128","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: The CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.04.001_bib129","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2026.04.001_bib130","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2026.04.001_bib131","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib132","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.04.001_bib133","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.2019004205","article-title":"Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib134","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Gui\u00e8ze","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2026.04.001_bib135","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2022016040","article-title":"Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy","volume":"140","author":"Thijssen","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.semcancer.2026.04.001_bib136","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1038\/s41375-025-02694-4","article-title":"Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies","volume":"39","author":"Chong","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.04.001_bib137","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2022016600","article-title":"Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples","volume":"142","author":"Khalsa","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcancer.2026.04.001_bib138","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2026.04.001_bib139","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood.2021014304","article-title":"Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies","volume":"140","author":"Thomalla","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib140","doi-asserted-by":"crossref","first-page":"7836","DOI":"10.1021\/acs.jmedchem.4c00027","article-title":"Discovery of the clinical candidate sonrotoclax (BGB-11417), a highly potent and selective inhibitor for both WT and G101V mutant Bcl-2","volume":"67","author":"Guo","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.semcancer.2026.04.001_bib141","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood.2023019706","article-title":"Sonrotoclax overcomes BCL2 G101V mutation\u2013induced venetoclax resistance in preclinical models of hematologic malignancy","volume":"143","author":"Liu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.04.001_bib142","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1158\/1078-0432.CCR-22-3321","article-title":"Novel BCL-2 inhibitor lisaftoclax in relapsed or refractory chronic lymphocytic leukemia and other hematologic malignancies: first-in-human open-label trial","volume":"29","author":"Ailawadhi","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.semcancer.2026.04.001_bib143","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41375-025-02662-y","article-title":"Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice","volume":"39","author":"Blombery","year":"2025","journal-title":"Leukemia"},{"issue":"7873","key":"10.1016\/j.semcancer.2026.04.001_bib144","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X26000453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X26000453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:42:10Z","timestamp":1778794930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X26000453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":144,"alternative-id":["S1044579X26000453"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2026.04.001","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy-driven clonal dynamics in chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}